IL6 and triple-negative breast carcinoma: For example, HMGA2 mediated the occurrence of triple-negative breast cancer by activating the NF-kB/IL-6/IL-8/STAT3 axis (37); HMGA2 activated the mTOR signaling pathway to inhibit ferroptosis, thereby enhancing the death resistance of pancreatic cancer and reducing chemotherapy sensitivity (38).